May 7 |
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
|
May 6 |
Sagimet Biosciences gets new finance head
|
May 6 |
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
|
Apr 26 |
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
|
Apr 22 |
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
|
Mar 27 |
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
|
Mar 25 |
Sagimet stock jumps 23% in wake of Q4 report, business updates
|
Mar 25 |
Sagimet Biosciences GAAP EPS of -$2.66 beats by $34.65, revenue of $2M in-line
|
Mar 25 |
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
|
Mar 25 |
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
|